Validant acquires IDEC, a leading regulatory consultancy in Japan

Posted: 2 Dec 2020
  • Expands geographic reach with direct presence in Japan
  • Expands breadth and depth of consultancy and implementation capabilities
  • Establishes comprehensive Asian regulatory service with DataRevive in China and IDEC in Japan

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its portfolio company, Validant, regarding the acquisition of IDEC.

Validant, a leading transatlantic quality, compliance and regulatory consulting group (‘the Group’), has acquired IDEC, a leading regulatory consultancy in Japan. IDEC supports customers from across the globe and helps them navigate the Japanese market by providing strategic advice and hands-on implementation support.

IDEC is uniquely positioned to support international and local customers operate in a complex and challenging regulatory environment. The business is led by CEO, Naoya Kato, and a team of highly experienced regulatory affairs professionals with an international background. IDEC provides a full service regulatory and commercialization offering allowing customers to have a virtual presence in Japan. This model allows for a more strategic and efficient process for firms looking to enter the Japanese market.

Validant’s acquisition of IDEC is another important step in its international growth strategy, focused on combining best-in-class regulatory and quality providers, and accelerating their growth with further investment. It follows the acquisition of DataRevive in 2019, a regulatory strategy and consultancy for global clients, based in Washington D.C.

The combination expands the Group’s geographic presence with an office in Tokyo and, together with DataRevive, which recently established a Chinese office, creates a strong base to establish a broader Asian regulatory practice.

Commenting on the announcement, Brian Burns, CEO of Validant said: “We are delighted to announce the acquisition of IDEC and welcome Naoya Kato and his team into the Validant family. Today’s announcement is another important milestone to achieving our ambition to extend our position as the leading quality, compliance and regulatory consulting firm in the healthcare sector globally, as we integrate IDEC’s leading expertise in the Japanese market into the wider Validant offering.”

Chris Brünger, Founder and Chairman of IDEC, said: “It is an exciting time for IDEC to be joining forces with Validant, a company that shares our philosophy and approach in providing the highest quality services to support customers with complex regulatory needs”.

Naoya Kato, CEO of IDEC, said: “It is our pleasure to start a new era as a member of the Validant family to establish a truly global regulatory consulting platform. I look forward to working with the Validant team to combine our expertise and networks to maximize the potential of the business, grow our customer base, and provide the highest value through strategic advice and support of regulatory, clinical, and commercial implementation for speedy development and a successful global product launch.”

Further information:
GHO Capital Partners LLP
T +44 20 3700 7440
[email protected]

About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities in Europe, building market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to unlock value in a global system that demands the delivery of better, faster, more accessible healthcare . For further information, please visit

About Validant
Validant is a leading international Quality, Compliance, and Regulatory consulting firm, blending industry expertise with innovation to create custom solutions for companies on the frontier of health. With deep experience working within and alongside the FDA and other regulatory agencies, we understand how to navigate the complexities facing today’s healthcare industry. For further information, please visit

About IDEC
Founded in 2003, IDEC Inc. has ever since enabled its clients to develop and obtain regulatory approval for their innovative treatments in Japan without significant delay compared to the US and EU.

The IDEC team of experts understands the challenges of developing drugs for Japan, both on a standalone basis and through partnerships, and can assist our clients design and implement new strategies for Japan.

IDEC offers its professional services as the “Virtual Japan Team” for its clients, focusing on providing high value-added R&D and market access services. IDEC also provides hands-on implementation to lead Japanese development programs.. For further information, please visit